Inari Medical (Nasdaq:NARI) announced today that the FLASH registry evaluating its FlowTriever produced positive results. The company designed its FlowTriever for device retrieval and aspiration. The system treats pulmonary embolism (PE). FlowTriever non-surgically removes clots from peripheral blood vessels. Its uses include treatment for PE and clots in transit in the right atrium. It received […]
Transcatheter Cardiovascular Therapeutics symposium (TCT)
4 major cardiology trends you need to know from TCT 2022
Medtronic, Edwards and Abbott presented positive data as TAVR, TEER and renal denervation innovations continue to arrive. The 34th Transcatheter Cardiovascular Therapeutics (TCT) conference took place in Boston this past week and a ton of big names made waves with their technologies and innovations. Medtronic, Abbott, Edwards and Boston Scientific represent a few of the […]
Abiomed Impella heart pump performs well in Japan study
Abiomed (Nasdaq:ABMD) announced today that a three-year study in Japan demonstrated positive results for its Impella heart pump. Danvers, Massachusetts-based Abiomed’s study is an update to 2020 interim analysis. Results were presented at TCT 2022 in Boston. The investigator-led study evaluated all Impella-supported patients across 109 hospitals in Japan. Of the 1,344 AMI cardiogenic shock […]
ReCor Medical ultrasound renal denervation trial meets primary efficacy endpoint
ReCor Medical announced that a trial for its Paradise ultrasound renal denervation (uRDN) treatment met its primary efficacy endpoint. Palo Alto, California-based ReCor’s RADIANCE II pivotal trial evaluated Paradise as a treatment for hypertension. The trial operated under FDA investigational device exemption. ReCor presented results at TCT 2022 in Boston. They follow the company’s July […]
Medtronic presents positive data on TAVR, TMVR devices
Medtronic (NYSE:MDT) announced data from multiple trials supporting its transcatheter heart valve replacement devices. Data were presented at the 34th Transcatheter Cardiovascular Therapeutics (TCT) conference in Boston. Results covered the company’s self-expanding transcatheter aortic valve replacement (TAVR) devices and its transapical transcatheter mitral valve replacement (TMVR) system. Medtronic kicked off TCT by announcing the full […]
Study shows blood pressure reduction with Medtronic renal denervation procedure
Medtronic (NYSE:MDT) announced study data that it says demonstrates significant blood pressure reduction with the Symplicity renal denervation system. The SYMPLICITY HTN-3 clinical trial observed subjects who underwent radiofrequency renal denervation (RF RDN) with first-generation Symplicity. Results demonstrated a statistically significant reduction in office and ambulatory blood pressure compared to a sham control group. Medtronic’s […]
Boston Scientific Sentinel cerebral protection system does not meet primary endpoint
Boston Scientific (NYSE:BSX) announced that its PROTECTED TAVR clinical trial evaluating its Sentinel system missed its primary endpoint. Marlborough, Massachusetts-based Boston Scientific designed the Sentinel cerebral protection system to capture and remove embolic debris stemming from transcatheter aortic valve replacement (TAVR). The goal is to extract the debris before it can reach the brain and […]
Data reinforces value of Abbott MitraClip for treating MR
Abbott (NYSE:ABT) today announced post-approval study results supporting its MitraClip G4 system for treating mitral regurgitation (MR). The company presented data from the EXPAND G4 study at the 34th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation in Boston. EXPAND G4 evaluated MitraClip G4, the company’s transcatheter edge-to-edge repair (TEER) device […]
Medtronic fully launches its next-gen TAVR in U.S.
Medtronic (NYSE: MDT) marked the start of the TCT 2022 conference today by announcing the full U.S. launch of its Evolut FX TAVR system. The medtech giant’s next-generation TAVR won FDA approval in 2021, followed by a limited roll out earlier this year. Edwards Lifesciences —Medtronic’s major U.S. competitor in the transcatheter aortic valve replacement […]
TCT 2016: The best of the rest
The annual Transcatheter Cardiovascular Therapeutics conference went down in Washington, D.C., this week, with late-breaking study results beginning Oct. 29. After stents took center stage Day 1, with a raft of studies covering the latest on the bioresorbable front, transcatheter valve replacements were the focus on Day 2. Day 3 saw a wider variety of topics, […]
TCT 2016: Structural heart, drug-coated balloons take their turn on Day 3
The annual Transcatheter Cardiovascular Therapeutics conference is under way in Washington, D.C., with late-breaking study results beginning Oct. 29. We’ll update this post throughout the day as new results come in, so be sure to check back for the latest news out of TCT 2016. After stents took center stage Day 1, with a raft of […]
